Revolutionizing Weight Loss: India's Affordable Semaglutide Generics

Wed Mar 18 2026 11:09:13 GMT+0000 (Coordinated Universal Time)

The expiration of the patent on semaglutide in India heralds a new era for weight-loss treatments, promising cheaper alternatives and expanding access for millions battling obesity.

India is poised for a significant transformation in its obesity treatment landscape with the upcoming expiration of the patent for semaglutide, the active ingredient in popular weight-loss drugs like Wegovy and Ozempic. This development is expected to unleash a wave of affordable generic options, drastically reducing treatment costs and increasing accessibility to previously expensive weight-loss medications. Analysts forecast a surge in competition among Indian pharmaceutical companies, potentially generating a $1 billion market for semaglutide in India alone. However, doctors express concern about the quality and regulation of these generics amidst the growing obesity epidemic.

India could soon get a lot thinner - at least in theory.

On Friday the patent on semaglutide - the molecule behind Danish drugmaker Novo Nordisk's blockbuster weight-loss drugs Wegovy and Ozempic - expires in the country.

This will allow domestic pharmaceutical companies to release cheaper copies or generics, triggering a rush of competition that could slash prices by more than half and rapidly expand access for people in India, and eventually in other countries too.

Investment bank Jefferies has called it a potential magic-pill moment for India, predicting the semaglutide market could eventually reach $1bn domestically with the right pricing and uptake.

Analysts expect around 50 branded semaglutide generics to enter the market within months - a familiar pattern in India's fiercely competitive pharmaceutical industry. When the diabetes drug sitagliptin went off patent in 2022, about 30 branded versions appeared within a month and nearly 100 within a year.

India's pharmaceutical industry, currently worth about $60bn, is expected to double by 2030. Much of it is built on generics - a manufacturing muscle that now sets the stage for fierce competition over semaglutide. What has until now been an expensive injection largely confined to affluent patients could soon become far more common.

Originally developed to treat diabetes, these drugs are now being hailed as game changers for weight loss, offering results that few previous treatments could match. Semaglutide belongs to a class of medicines known as GLP-1 receptor agonists, which mimic a hormone that regulates appetite and blood sugar. By boosting insulin release and slowing the emptying of the stomach, the drugs make people feel full sooner and stay full longer.

Several Indian drugmakers are already preparing to make the move. According to Sheetal Sapale, vice-president at research firm Pharmarack, major firms including Cipla, Sun Pharma, Dr Reddy's Laboratories, Biocon, Natco, Zydus, and Mankind Pharma are readying branded generics, with many more likely to follow. Prices are expected to fall sharply.

Current monthly treatment costs are steep: Ozempic typically sells for 8,800 - 11,000 rupees ($95-$119); Wegovy can cost 10,000-16,000 rupees ($108-$173). Sapale expects generic competition to push that down to roughly 3,000-5,000 rupees ($36-54) per month. Lower prices could transform the market.

India's anti-obesity drug sector - covering both injectables and oral medicines - has already grown rapidly, from roughly $16m in 2021 to close to $100m according to Pharmarack. Demand accelerated after the launch of Rybelsus in 2022, the first oral version of semaglutide. The surge reflects a broader health shift.

Physicians report that access to affordable GLP-1 drugs could greatly expand treatment options for India's large population of patients with diabetes and obesity. However, concerns about misuse and the quality of newly available generics stir cautions among health professionals. Doctors warn against the potential of these drugs being misprescribed by unqualified individuals.

Despite the transformative potential, experts urge that the regulation of drug quality must be a priority. The Indian drug regulator has already cautioned pharmaceutical companies against unregulated direct-to-consumer promotions of weight-loss medications.